CellWell record HH-394090
Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
Fisher B; Costantino JP; Redmond CK; Fisher ER; Wickerham DL; Cronin WM
Journal of the National Cancer Institute ยท 1994
In plain language
In NSABP B-14, tamoxifen-treated women had a higher endometrial cancer rate than placebo, but liver, gastrointestinal, and urinary tract cancers were not increased, though part of the data was later found falsified.
- Evidence
- Established
- Design
- Randomized controlled trial
Cite this record: https://thecellwell.org/studies/HH-394090
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.